Michelin-rated chef arrested on domestic violence charges at West Palm Beach home
Jacob Bickelhaupt, the chef and owner of Konro restaurant, is facing one count each of domestic battery causing bodily harm and domestic battery following his arrest June 2 by West Palm Beach police.
According to his arrest report, Bickelhaupt repeatedly punched and kicked the woman, leaving her with two black eyes, and with swelling and bruising on her face.
The woman reportedly went to Palm Beach International Airport after the attack to try to buy a flight to her family's home but suffered a seizure at the ticket counter. She received emergency care at St. Mary's Medical Center.
During a hearing June 3 at the Palm Beach County Jail, Circuit Judge Daliah Weiss ruled that Bickelhaupt, 41, is indigent and assigned a public defender to represent him. She set his bail at $90,000 and ordered that he be placed on in-house arrest with an ankle monitor if he is released.
As a matter of policy, the county Public Defender's Office does not comment on active cases. After his arrest, Bickelhaupt requested to speak to an attorney and did not make other statements to investigators, his arrest report said.
More: Dwyer student accused of torching classmate's car faces 2 more 'retaliation' arson charges
The arrest marks the second time within the past decade Bickelhaupt has faced an allegation of domestic violence. In June 2017, Chicago police arrested him on charges that he assaulted a woman, throwing her to the ground and striking her in the head with a bottle, according to multiple published reports.
He pleaded guilty to a charge of simple battery and was ordered to undergo mandatory drug and alcohol testing, complete a domestic violence program and pay fines. Shortly after the Chicago arrest, Bickelhaupt closed 42 Grams, his popular restaurant on Chicago's north side that at one time also earned Michelin-star status.
In 2023, he opened Konro in West Palm Beach, on Park Place off South Dixie Highway near the Norton Museum of Art. It is a menu-free tasting restaurant with 10 counter seats and a steep, three-figure per person price tag for admission.
In 2024, the Michelin Guide announced it would be rating Palm Beach County's restaurants, and in April, Konro was awarded a single Michelin star, making it the county's first and only restaurant to carry a star from the vaunted guide.
According to Bickelhaupt's arrest report, his current accuser told investigators that he repeatedly attacked her over the span of two hours, even as she tried to leave the home. Once the attack stopped, the woman packed a bag and called for a ride to PBIA, where she collapsed, the arrest report said.
Officers detained Bickelhaupt that night and took him to police headquarters for questioning.
Julius Whigham II is a criminal justice and public safety reporter for The Palm Beach Post. You can reach him at jwhigham@pbpost.com and follow him on X, the platform formerly known as Twitter, at @JuliusWhigham. Help support our work: Subscribe today.
This article originally appeared on Palm Beach Post: Michelin-star chef arrested on domestic violence charges in West Palm
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 hours ago
- Business Wire
Alen Celebrates 20 Years of Innovation and Leadership in Air Purification For Home, School and Work
AUSTIN, Texas--(BUSINESS WIRE)-- Alen, a leader in the air purification industry, today celebrates 20 years of creating best-in-class air purifiers that ensure the health and safety for millions of Americans. The Austin-based company has become a trusted name in clean air solutions since its founding in 2005, recognized by leading industry and scientific experts for its powerful technology, thoughtful design and its deep commitment to healthier living. 'Alen began with one goal in mind. Make clean air simple, effective, and accessible, for people and pets,' said Warburg Lee, Founder and CEO of Alen. 'Since then, both outdoor and indoor air quality have worsened due to wildfires, increased allergens, and viruses, making our mission even more critical. We're a health and wellness company, not just an air purifier company, with a mandate to create healthy living and working environments. From our earliest models to our most recent advanced purifier models, our north star is that we remove 99.9 percent of airborne particulates while operating quietly in the background to protect what matters most.' 20 years of achievements include: Growing from start-up to nationally recognized brand with over 50 team members, availability in all 50 states, serving more than 2 million customers worldwide, and developing the fifth generation of advanced air purifier systems with new products launching in October 2025. Meeting critical third-party standards, including certifications from ENERGY STAR, Quiet Mark, SleepScore Labs, and the Asthma and Allergy Friendly Program. Products are tested to remove up to 99.9 percent of airborne particles down to 0.1 microns. Sought-after by national retailers including Lowe's and Amazon to carry Alen products because they are a trusted brand for homes, schools, and businesses across the country. Continued excellence in technology, developing proprietary technology, industry-first features, and responsive design with intelligent sensors and proprietary airID technology that detects and responds to real-time air quality changes, automatically adjusting to remove pollutants like dust, smoke, and chemicals for cleaner, healthier air. Day-one pursuit of design to fit the aesthetics of modern living. Alen purifiers blend seamlessly into bedrooms, offices, classrooms, and large commercial spaces with multiple sizes, ultra-quiet performance, and customizable designer panels. Alen's mission to improve indoor air became a national movement for wellness. Alen continues to lead with purpose, innovation, and a long-standing commitment to help people breathe better and live healthier. Alen is preparing to introduce new models later this year, building on its reputation for premium air purification and breakthrough technology. These upcoming releases will reinforce its position as a leader in clean air solutions. Alen is poised to deliver greater impact across both retail and business-to-business markets, backed by ongoing innovation, supply chain strength, and strategic commercial partnerships. To explore Alen's full range of air purification solutions, visit About Alen Alen is an Austin-based innovator of high-performance air purifiers, committed to creating healthier indoor environments through advanced, scientifically validated technology. Alen's purifiers use True HEPA filters and are independently certified by Quiet Mark, the Asthma & Allergy Friendly® Certification Program, SleepScore Labs, and ENERGY STAR® for delivering best-in-class air purification, energy efficiency, ultra-quiet operation, and improved sleep quality. Alen's mission to enhance quality of life in homes, workplaces, and shared spaces is driven by the belief that wellness begins with pure air. Alen empowers individuals and families to lead healthier lives with cleaner, safer air and greater peace of mind through proprietary features like airID smart sensor technology and a commitment to lifetime reliability.
Business Wire
a day ago
- Business Wire
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. 'Delivering on navenibart's best-in-class potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial is well underway with active sites across the U.S., U.K., Canada, Hong Kong, and South Africa' said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "We are encouraged by the strong enthusiasm from patients and physicians, including at the recent HAEA conference, where we had the opportunity to engage with the HAE community. We were also thrilled to announce a strategic partnership with Kaken. Their expertise supports our ongoing Phase 3 enrollment, contributes to strengthening our financial position, and may ultimately help expand global patient access to navenibart.' Navenibart (STAR-0215) In August, Astria announced that it has exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical for navenibart. Under the agreement, Astria will receive an upfront payment of $16 million, with the potential for an additional $16 million in total commercialization and sales milestones. In addition to these payments, Astria is also eligible for tiered royalties with the royalty rate as a percentage of net sales up to 30%, and partial Phase 3 cost reimbursement. The navenibart Phase 3 program consists of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial, which are designed to support registration globally. ALPHA-ORBIT is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of navenibart over a 6-month treatment period, with dosing arms every 3 months (Q3M) and every 6 months (Q6M). Enrollment is ongoing and top-line results are expected in early 2027. After completing ALPHA-ORBIT, eligible patients may continue into the open-label ORBIT-EXPANSE study, which includes 6 months of additional treatment followed by a patient-centric flexible dosing phase. Positive initial results from the ongoing ALPHA-SOLAR long-term open-label trial of navenibart were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. All 16 ALPHA-STAR target enrollment participants continued into ALPHA-SOLAR and the results are highly consistent with ALPHA-STAR - showing robust overall reduction in monthly attack rates (92% mean and 97% median) and a well-tolerated safety profile. STAR-0310 Astria is developing STAR-0310, an investigational high-potency and long-acting monoclonal antibody OX40 antagonist that incorporates YTE technology, for the treatment of atopic dermatitis (AD) and potentially other indications. STAR-0310 was intentionally designed to capitalize on the learnings of OX40 receptor and OX40 ligand programs with the goal of having the best overall OX40 therapy. The Company initiated a Phase 1a clinical trial of STAR-0310 in healthy subjects in January 2025. The Phase 1a trial is intended to assess the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy adult participants, with early proof-of-concept (POC) results expected in the third quarter of 2025. Data presented at the European Academy of Allergy and Clinical Immunology (EAACI) annual congress support STAR-0310 as a potential best-in-class OX40 antagonist, with a unique allosteric inhibition mechanism, enhanced disruption of OX40/OX40L signaling compared to other agents, and pure antagonistic activity without agonism. These findings, along with previously reported low ADCC activity and robust cytokine suppression, highlight STAR-0310's differentiated profile and its potential to achieve deeper inhibition of T cell responses. Upcoming Corporate Events Cantor Global Healthcare Conference (September 3-5, 2025, New York, New York) Second Quarter 2025 Financial Results Cash Position: As of June 30, 2025, Astria had cash, cash equivalents and short-term investments of $259.2 million, compared to $328.1 million as of December 31, 2024. The Company expects that its cash, cash equivalents and short-term investments as of June 30, 2025, together with the Kaken upfront payment and expected reimbursement of a portion of the Company's Phase 3 program costs, will be sufficient to fund its current operating plan into 2028, including (i) for navenibart, support for all program activities through completion of our ALPHA-ORBIT Phase 3 trial, including activities related to the planned ORBIT-EXPANSE long-term trial and Phase 3 development and testing of drug device combinations, and (ii) for STAR-0310, the completion of the ongoing Phase 1a clinical trial of healthy subjects. Net cash used in operating activities for the three months ended June 30, 2025 was $36.1 million, compared to $16.8 million for the three months ended June 30, 2024. R&D Expenses: Research and development expenses were $25.9 million for the three months ended June 30, 2025, compared to $20.7 million for the three months ended June 30, 2024. The increase in research and development expenses was attributed to an increase in navenibart expenses related to the support of the ALPHA-ORBIT clinical trial and employee expenses, partially due to increases in stock-based compensation and company growth to support the advancement of our programs, during the three months ended June 30, 2025. G&A Expenses: General and administrative expenses were $9.9 million for the three months ended June 30, 2025, compared to $8.1 million for the three months ended June 30, 2024. The increase in general and administrative expenses was attributable to company growth to support the advancement of our programs, stock-based compensation and other professional services. Operating Loss: Loss from operations was $35.8 million for the three months ended June 30, 2025, compared to $28.8 million for the three months ended June 30, 2024. Net Loss: Net loss was $33.1 million for the three months ended June 30, 2025, compared to a net loss of $24.2 million for the three months ended June 30, 2024. Net Loss Per Share Basic and Diluted: Net loss per share basic and diluted was $0.57 for the three months ended June 30, 2025, compared to a net loss basic and diluted of $0.43 per share for the three months ended June 30, 2024. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is an investigational monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: the expected timing of receipt of topline results from the navenibart ALPHA-ORBIT Phase 3 trial; the goals and objectives of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial, including that they are designed to support registration of Q3M and Q6M navenibart administration; our goal of developing two dosing options for navenibart; the potential for navenibart in the HAE market, including the potential to be the market leading treatment in HAE, the potential therapeutic and other benefits of navenibart as a treatment for HAE, and our vision and goals for the program; the objectives, goals and potential payments from our agreement with Kaken Pharmaceutical; the potential therapeutic benefits and potential attributes of STAR-0310 as a treatment for AD; expectations regarding the nature and timing of receipt of early proof-of-concept results from such trial, including our expectation that such results will inform on STAR-0310's differentiated profile; the potential to develop STAR-0310 in additional indications; our goals and vision for STAR-0310; statements about the Company's current operating plan and the Company's anticipated cash runway; and the goal of bringing life changing therapies to patients and families affected by allergic and immunological diseases and to become a leading allergy and immunology company. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'goals,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of Astria's product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the following risks and uncertainties: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies, including of navenibart and STAR-0310, may not be replicated in clinical trials, that the preliminary or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the navenibart Phase 1a clinical trial and the initial results from the ALPHA-STAR trial, may not be replicated in later stage clinical trials, including additional and final results from the ALPHA-STAR trial or the planned navenibart Phase 3 development program; the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the FDA and other regulatory authorities on our regulatory and clinical trial submissions and other feedback from potential clinical trial sites, including investigational review boards at such sites, and other review bodies with respect to navenibart, STAR-0310, and any other future development candidates, and devices for such product candidates; our ability to manufacture sufficient quantities of drug substance and drug product for navenibart, STAR-0310, and any other future product candidates, and devices for such product candidates, on a cost-effective and timely basis, and to develop dosages and formulation for navenibart, STAR-0310, and any other future product candidates that are patient-friendly and competitive; our ability to develop biomarker and other assays, along with the testing protocols therefore; our ability to obtain, maintain and enforce intellectual property rights for navenibart, STAR-0310, and any other future product candidates; our potential dependence on collaboration partners; competition with respect to navenibart, STAR-0310, or any of our other future product candidates; the risk that survey results and market research may not be accurate predictors of the commercial landscape for HAE, the ability of navenibart to compete in HAE and the anticipated position and attributes of navenibart in HAE based on clinical data to date, its preclinical profile, pharmacokinetic modeling, market research and other data; risks with respect to the ability of STAR-0310 to compete in AD and the anticipated position and attributes of STAR-0310 in AD based on its preclinical profile; our ability to manage our cash usage and the possibility of unexpected cash expenditures; our ability to obtain necessary financing to conduct our planned activities, including the costs associated with commercialization of navenibart if regulatory approval is obtained, and to manage unplanned cash requirements; the risks and uncertainties related to our ability to recognize the benefits of any additional acquisitions, licenses or similar transactions; and general economic and market conditions; as well as the risks and uncertainties discussed in the 'Risk Factors' sections of our Annual Report on Form 10-K for the period ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and in other filings that we may make with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Astria may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on Astria's forward-looking statements. Neither Astria, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Astria's views as of any date subsequent to the date hereof. Astria Therapeutics, Inc. C onsolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) Astria Therapeutics, Inc. Selected Consolidated Balance Sheets Data (In thousands) (Unaudited) June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 76,319 $ 59,820 Short-term investments 182,859 268,312 Right-of-use asset 4,546 5,114 Other current and long-term assets 18,200 9,117 Total assets 281,924 342,363 Liabilities and stockholders' equity Current portion of operating lease liabilities 1,399 1,384 Long term portion of operating lease liabilities 3,367 3,969 Other current and long-term liabilities 16,645 17,747 Total liabilities 21,411 23,100 Total stockholders' equity $ 260,513 $ 319,263 Expand Astria Therapeutics, Inc. Selected Consolidated Statements of Cash Flows Data (In thousands) (Unaudited) Six Months Ended June 30, 2025 2024 Net cash used in operating activities $ (70,076 ) $ (35,885 ) Net cash provided by (used in) investing activities 86,575 (194,334 ) Net cash provided by financing activities - 141,901 Net increase (decrease) in cash, cash equivalents and restricted cash $ 16,499 $ (88,318 ) Expand
Yahoo
2 days ago
- Yahoo
Florida restaurant stripped of Michelin star after owner-chef's arrest on attempted murder charges
A Florida restaurant has been stripped of its Michelin star after its owner-chef was jailed on domestic violence charges that have since been upgraded to attempted second-degree murder. Konro, once hailed as Palm Beach County's first Michelin-starred restaurant, has been removed from the prestigious guide. The demotion happened after Jacob Bickelhaupt, 41, was arrested in June on domestic violence charges stemming from a June 2 attack on a woman that police say lasted roughly two hours. He has pleaded not guilty. Michelin spokesperson Carly Grieff told the South Florida Sun Sentinel that the star was pulled because the restaurant 'has closed.' But in June, after the chef's arrest, Michelin told the Sun Sentinel that while it 'firmly condemns all acts of violence, aggression and harassment,' it was taking no immediate action, arguing that 'MICHELIN Stars are annual distinctions and therefore our Inspectors revisit the restaurants annually.' Konro, a 10-seat chef's counter named for the Japanese charcoal grill used in many of its courses, seems to have closed following Bickelhaupt's arrest – just two months after winning Palm Beach County's first Michelin star. Dishes included Japanese A5 Wagyu, edible floral microgreens, and foie gras in chicken-skin cones with cloudberry jam, the Tampa Bay Times reported. The alleged assault happened when the victim, a woman who worked with Bickelhaupt, allegedly tried to coax him from the couch back to bed, according to a probable cause affidavit. Police say he punched and kicked her repeatedly, even as she crawled away. She eventually escaped, calling a rideshare to Palm Beach International Airport to return to her home in Denver. But she suffered a seizure and was rushed to St. Mary's Medical Center, where doctors told her family she would likely have died if she had boarded the flight. The woman first claimed she'd been in a car accident, but medical staff told deputies her injuries, which included two black eyes, extensive bruising, and a subdural hematoma requiring emergency surgery, were inconsistent. In a sworn statement, she named Bickelhaupt as her attacker. Deputies later found blood in multiple rooms of his home. Bickelhaupt has faced similar allegations before. In 2017, police charged him with striking his then-wife, Alexa Welsh, in the head with a bottle, forcing his acclaimed Chicago restaurant 42 Grams to close the next day. Bickelhaupt admitted: 'I hurt her bad and I freaked out … I asked [an employee] to call 911 and left in a panic back to my apartment. I had a bunch of beer and whiskey at home and was going to kill myself.' He later pleaded guilty to simple battery. His ex-wife Welsh told the Sun Sentinel she was unsurprised by the latest case. 'Violence is a cycle. How does the saying go? 'Those who do not learn history …' I sent [the victim] a message of support. I hope she's able to make a full recovery.' The victim's current condition is unknown. Bickelhaupt remains in Palm Beach County jail and faces charges of attempted second-degree murder and false imprisonment. His next hearing is scheduled for September 8.
